Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

SanofiNASDAQ: SNY

Operating Expenses · Q2 FY2026 · quarter ended Jun 2026

Operating expenses grows, but more slowly than its trailing trend

Q2 FY2026 operating expenses of €6.9B rose 10.0% year over year, behind the +24.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 18.2% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.

Context

  • Operating expenses amounted to 51.5% of revenue in FY2025, down 2.3 pp from a year earlier.
  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +10.0% toward the trailing-twelve-month pace of +24.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€6.9B+18.2% QoQ
Last fiscal yearDec 2025
€24.07B+1.0% YoY
LTMJun 2026
€28.48B+24.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.0%——
1 year+1.0%——
3-year CAGR+9.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

EUR · from the income statement

Latest · FY2025
24.07B EUR
Year-over-year change
+1.0%
4-year CAGR
+6.4%

Operating Expenses vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +24.0% is the 4th highest of 11, against a peer median of +2.2%.
  • Operating expenses amounts to 58.2% of revenue for SNY, versus a peer median of 45.2%.
SNY Competitors
Operating Expenses for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 123.58B DKK+3.8%+18.5%37.5%
MRKMerck & Co., Inc.LTM Jun 2026$38.99B USD+46.3%-0.5%58.7%
AZNAstraZeneca PLCLTM Sep 2026$35.08B USD-0.0%+6.8%56.4%
PFEPfizer Inc.LTM Jun 2026$29.59B USD+0.7%+0.5%46.5%
SNYSanofiLTM Jun 2026€28.48B EUR+24.0%+9.1%58.2%
LLYEli Lilly and CompanyLTM Jun 2026$26.83B USD+24.4%+22.6%33.7%
GILDGilead Sciences, Inc.LTM Jun 2026$25.73B USD+76.1%-7.0%84.5%
NVSNovartis AGLTM Jun 2026$24.42B USD-3.8%+0.2%43.9%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$20.67B USD-12.3%-8.6%42.0%
GSKGSK plcLTM Jun 2026£17.27B GBP-1.0%+4.7%52.0%
AMGNAmgen Inc.LTM Jun 2026$15.05B USD+5.1%+14.0%39.5%
Peer median (excluding SNY) —+2.2%+2.6%45.2%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.